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Background: Because of its minimally invasive and highly accurate nature, the use of Mammotome, a vacuum-assisted
breast biopsy device has proven beneficial to the treatment of benign breast lesions. Taking advantage of endoscopic
and Mammotome techniques together, we utilized the Mammotome device for therapeutic excision of malignant
lesions in breast-conserving surgery (BCS).
Methods: Between December 2009 and January 2010, two patients with early breast cancer received
Mammotome-assisted endoscopic BCSs. Under ultrasound monitoring, the Mammotome system dissected
the surrounding tissue and freed the tumor en bloc leaving negative margins; endoscopic axillary lymph node
dissection then followed.
Results: The operation time was less than 180 minutes and the mean blood loss was 60 ml. The post-operative
pathology report confirmed two patients to have invasive ductal carcinoma, one without axillary lymph nodes
metastasis (0/11) and the other with one lymph node metastasis (1/21). No adverse events were noted. During a mean
follow-up of 26.5 months, no evidence of recurrence or metastasis was found. The patients were satisfied with the
cosmetic results.
Conclusions: Mammotome-assisted endoscopic surgery appears to be a valuable option for early breast cancer.
The long-term therapeutic effect remains to be confirmed.
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One of the current standards of approach for early-stage
breast cancer is breast-conserving surgery (BCS) [1].
However, clinically, a minority of breast cancer patients
with BCS are still dissatisfied with their cosmetic outcome
[2,3]. In order to avoid the obvious incision of the breast
and obtain a better cosmetic outcome, endoscope-assisted
surgery has been adapted in BCS, but the applications are
restricted because of the long operation time involved and
relatively large blood loss [4].
The most commonly used vacuum-assisted biopsy device,
Mammotome (Ethicon Endo-surgery, Inc., Cincinnati, OH,
USA), has been successfully employed for excision of be-
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reproduction in any medium, provided the orpapillomas due to its advantages of minimal invasiveness
and more precise tissue harvesting [5,6]. However, until
now, there have been few reports on its application in
resecting malignant breast tumors. In this study, we used a
Mammotome-assisted endoscopic technique to excise the
early breast cancer, improve the accuracy and completeness
of excision and acquire a better appearance in two patients.Methods
Between December 2009 and January 2010, two patients
underwent Mammotome-assisted endoscopic excision
technique of a preoperatively diagnosed invasive breast
cancer at our hospital. Table 1 summarizes their charac-
teristics. The two patients were women. On examination,
one patient’s tumor was localized in the upper-outer
quadrant of the left breast near the axilla (2.1 cm maximum
diameter) and one enlarged lymph node which mightThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Clinical characteristics of the two patients before surgery
Patient number Age/sex Tumor size (cm) TNM Hormone status HER-2 NACT regimen Tumor size (cm) after NACT
1 57/F 2.1 T2N1M0 + - Docetaxel + epirubicin 0.9
2 41/F 3.0 T2N0M0 + - Docetaxel + epirubicin 0.96
NACT: Neoadjuvant chemotherapy.
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by ultrasonography (clinical stage: T2,N1,M0). The other
patient’s tumor was 3.0 cm in maximum diameter and
localized in the upper-inner quadrant of the left breast
by preoperative ultrasonography (clinical stage: T2,N0,
M0). Both patients’ hormone receptor status was estrogen
receptor (ER)/progesterone receptor (PR) positive and
epidermal growth factor receptor 2 (HER-2) negative. After
four cycles of neoadjuvant chemotherapy with the DE
regimen (docetaxel 75 mg/m2 and epirubicin 80 mg/m2
on day 1, every 2 weeks), ultrasound examinations
showed that the tumors were reduced to 0.90 cm and
0.96 cm respectively in the maximum diameter and partial
remission was achieved according to tumor response
criteria (Response Evaluation Criteria in Solid Tumors,
RECIST) [7]. All patients underwent Mammotome-assisted
endoscopic breast-conserving surgery. The surgical pro-
cedures are described below.
Consent
Written informed consent was obtained from all the
patients for publication of this report and any accom-
panying images.
Surgical procedures
The patient was placed in the supine position, with the arm
abducted to 90° after the induction of general anesthesia.
The cutting edges were marked at a distance of 5 mm from
the tumor, and at the lower exterior margin of the breast,
the intersection points of the nipple level line and anterior
border of the latissimus dorsi muscle were marked as the
puncture sites for the Mammotome (Figure 1A). The
lipolysis solution (250 ml of saline, 250 ml of distilled
water, 1 mg epinephrine and 400 mg lidocaine) was
injected into the subcutaneous space above the lesion,
retromammary spaces and axillary fossa. A 5-mm incision
was made in the skin at nipple level Mammotome punc-
ture site and then an 8G probe was inserted into the
posterior of the tumor via the retromammary spaces
under ultrasonic guidance. The probe aperture was
turned facing up towards the tumor and after rotation
of the probe, the first 12 biopsies were taken and the
deep, superior, inferior and superficial margins of the
tumor were removed. Then, another 5-mm incision
was made at the lower exterior margin of breast as the
second puncture site, the Mammotome probe was
inserted into tumor area, a further seven biopsies were
taken and the medial and lateral margins of the tumorwere resected (Figure 1B). All of the tissue margins
were shown to be negative by intra-operative frozen
section analysis (FSA). Sufficient liposuction was performed
in the axillary, subcutaneous and retromammary spaces of
the breast via the two Mammotome puncture sites using a
metal aspiration tube with a side aperture (a suction tip
used for uterine curettage); (Figure 1C). Another 5-mm
incision was made at the upper exterior margin of the
breast areola, with two Mammotome puncture sites as
trocar sites. CO2 pressure was infused into the axilla to
approximately 8 mmHg and then a 30-degree 10-mm
endoscope was inserted into the subcutaneous space
through the trocar sleeve. The trocar sleeve was placed
in the lower exterior margin incision of breast, and the
operating instruments were inserted into the other two
trocars (Figure 1D). Under endoscopy, we found the
tumor had been almost dissected (Figure 1E). Fibrous
tissues connected with the tumor were removed and
then levels I and II axillary lymph nodes were dissected
endoscopically. The endoscopic dissection method of
axillary lymph nodes was described previously [8]. The
dissected tumor and axillary specimen (Figure 1F) were
extracted through the axillary incision. A suction drainage
tube was inserted into the axillary space through the
inferior trocar hole.
The anesthesia and positioning of patient 2 was same
as patient 1. The cutting edges were marked at a distance
of 5 mm from the tumor. The intersection points of
the cutting edges extension line with the upper margin
of areola and the upper exterior margin of the breast
were marked as skin puncture sites of the Mammotome
(Figure 2A). After injecting lipolysis solution, normal
tissues on the marked cutting edges around the tumor
were excised by the Mammotome device under ultra-
sound guidance. The resected tissue was obtained for
intra-operative FSA and was shown to have negative
margins. A 3-cm peri-areolar incision was made, and the
subcutaneous space from the incision to the cavity around
the tumor was freed. The small amount of mammary
gland tissue remaining connected around the lesion was
removed. The tumor was dissected and removed via the
incision (Figure 2B, and C). A 10-mm incision was made
in the lower exterior margin of breast, and another 5-mm
incision was made at the intersection point of anterior
border of the latissimus dorsi muscle and the nipple
level line. Lipolysis and liposuction of the axillary fossa
and endoscopic axillary lymph node dissection were
performed as mentioned above.
Figure 2 The Mammotome-assisted endoscopic breast-conserving surgery used for case 2. (A) Cutting edges of tumor and axilla were
marked. (B) Dissected tumor and the surrounding normal tissues. (C) Ultrasound assessment for the Mammotome procedure and schematic
representation of Mammotome excision.
Figure 1 The detailed process of the Mammotome-assisted endoscopic breast-conserving surgery for case 1. (A) The edges of the tumor
to be cut and the axillary border were marked. (B) The tissues in inferior margin of tumor were removed. (C) The fat was aspirated. (D) Endoscope and
operating instruments were inserted into the subcutaneous space. (E) Tumor’s endoscopic image. (F) Resected specimens.
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The operation time and the blood loss of each patient is
shown in Table 2. The pathology report was that the
margins (medial, lateral, superior, inferior, superficial,
and deep) of each breast mass were uninvolved with
tumor. Two cycles of chemotherapy with DE regimen
were administered post-operatively. Post-operative ra-
diation therapy was administered, followed by endocrine
therapy. The post-operative pathology report confirmed
the two patients as having invasive ductal carcinoma,
but no metastases were demonstrated in the dissected
axillary lymph nodes (0/11) of one, and one lymph
node metastasis (1/21) was demonstrated in the other.
The patients received follow-up evaluation every six
months. They remained well and disease-free for over 26
months after the operation. No evidence of recurrence
or metastasis was found. No adverse events associated
with endoscopic axillary lymph node dissection had been
observed at the time of writing. Furthermore, two patients
were very satisfied with the cosmetic results (Figure 3A
and B for patients 1 and 2, respectively).
Discussion
Endoscopic surgery has been used in the treatment of
breast cancer for over a decade [9-12]. As a minimally
invasive technique, endoscopic surgery has prominent
advantages over the traditional open approach. Many
clinical trials have demonstrated that endoscope-assisted
BCS is safe and feasible for early-stage breast cancer
[13,14]. Ultrasound-guided Mammotome biopsy is widely
recognized as an accurate and valuable option for the
diagnosis of breast lesions [15], and this procedure has
recently been highly recommended and increasingly
applied in the treatment of benign breast lesions [5,6].
However, it has rarely been recommended for malignant
breast tumor removal in accordance with the en bloc
resection principle of malignant tumors.
Employing the advantages of the Mammotome, we
expected that a vacuum-assisted biopsy system could
be used to remove non-cancerous surrounding tissues
before performing complete excision of a small size tumor
rather than directly cutting the tumor into pieces. In our
studies, we combined the Mammotome and endoscopic
techniques in BCS and used the Mammotome system
for therapeutic excision of malignant lesions. Under
ultrasound guidance, the Mammotome system facilitated













1 175 0/11 70 10 387
2 150 1/21 50 7 227thickness, around the tumor, and each specimen was sent
for intra-operative FSA. Using this technique, after the
tumor had been almost completely separated, we could
conserve the normal breast tissue adjacent to the tumor
as much as possible. If the distance between tumor and
nipple was < 3 cm, the residual breast tissues contiguous
to the tumor could be excised through a peri-areolar
incision to perform wide local excision surgery. If the
tumor-nipple distance was > 3 cm, the tumor dissection
could be performed via the endoscopic approach.
Endoscopic axillary lymph node dissection was per-
formed with three trocars individually located at the lower
exterior margin of the breast, the upper exterior margin of
the areola, intersection points of the nipple level line and
the anterior border of the latissimus dorsi muscle (some
of these trocar sites could also serve as Mammotome
puncture sites). The axillary specimens were extracted
from the axillary incision, and the dissected tumor was
extracted from the axillary or the peri-areolar incision.
A number of researchers have limited their clinic trials
of endoscopic breast cancer surgery to T1 and small T2
tumors [12,16]. Based on our practice, the size and
location of the tumor and the tumor-nipple distance
should be assessed carefully in Mammotome-assisted
endoscopic BCS, because oncologic safety and the conveni-
ence of the operation should be given full consideration
[17]. The maximum tumor diameter of both patients
presented herein was reduced to <1 cm after neoadjuvant
chemotherapy. The cutting edges of the Mammotome
were 5 mm away from the tumor, and all margin tissues
were confirmed to be negative by intra-operative FSA.
Theoretically, breast cancer patients with tumors <2 cm in
size, located >2 cm from the areola and without invasion
of the skin and pectoralis major muscle can safely undergo
Mammotome-assisted endoscopic BSC.
An important purpose of this surgery is to obtain better
cosmetic results. Small incisions were made in a distal and
poorly-visible area with access the tumor, which was then
removed with the Mammotome and endoscopic surgery
technique. In the two patients described herein, we made
another skin incision around the areola or in the axillary
fossa through which to excise and remove the tumor, and
no breast skin incision or obvious scar was detectable at
the operation site. These two patients were very satisfied
with the post-operative cosmetic results. No recurrence










Docetaxel + epirubicin Yes 27 None
Docetaxel + epirubicin Yes 26 None
Figure 3 Pre- and post-operative images of case 1 and case 2. (A) Case 1, 18 months after surgery. (B) Case 2, 12 months after surgery.
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removal of malignant tumors have been described previ-
ously with better cosmetic outcome than the conventional
BCS [14]. However, in open surgery or under an endo-
scope, without real-time ultrasonic guidance, it is difficult
to achieve precise excision of tumor margin along the
pre-drawn excision line. Moreover, the traction during
operation may cause the actual cutting edges to deviate
from the pre-drawn lines, which may lead to insufficient
dissection or over-dissection. In Mammotome-assisted
endoscopic BCS, the surgeon can accurately dissect the
tumor margin and free the tumor under real-time ultra-
sonic guidance, thereby avoiding deviation from actual
excision lines from the pre-drawn ones. Although in case
2, the length of the incision may not show significant
advantage compared with minimally invasive open surgery,
we believe that the length and location of the incisions can
be further improved with the accumulation of our surgical
experience.
Conclusions
In conclusion, this is the first time that a combinative
use of Mammotome and endoscopic surgery techniques
to perform the en bloc resection of breast cancer has
been reported. We advocate that Mammotome-assisted
endoscopic BCS should be a safe and effective technique
for minimally invasive tumor excision with a safety mar-
gin in early-stage breast cancer. Additionally, this novel
surgical approach could also provide a significantly better
cosmetic outcome than conventional lumpectomy for
well selected patients. Nevertheless, there are somedisadvantages to this technique which are as follow:
patients with tumor >2 cm are not suitable for this
method; the operation time is longer than that of open
surgery; and the operation can only be successfully
performed by a surgeon experienced in endoscopic and
Mammotome techniques. Moreover, the long-term thera-
peutic effect still requires further confirmation with a
large-sample clinical trial and long-term follow-up.
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